Evidence map›Paper›PMID 21115952›Full record

ArticleNeurology2010

Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study.

E M C Schrijvers, J C M Witteman, E J G Sijbrands, A Hofman, P J Koudstaal, M M B Breteler

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04705220 (Effect of Nutritional Supplementation With Turmeric on the Cognitive Performance of Subjects With Metabolic Syndrome), which is not on this map. Cited by 170 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 4 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04705220 nacompletednot on this mapstarted 2022, after this paper: background citation

Effect of Nutritional Supplementation With Turmeric on the Cognitive Performance of Subjects With Metabolic Syndrome

TypeinterventionalSponsorIndena S.p.ARan2022 to 2025Enrolled85ConditionsMild Cognitive ImpairmentArmsMERIVA® Tablets, Placebo Tablets
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 4 syntheses or guidelines pooled it, 328 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Drug repositioning for Alzheimer's disease.Nature reviews. Drug discovery · 2012
    Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

E M C SchrijversDepartment of Epidemiology, Erasmus MC University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
J C M Witteman
E J G Sijbrands
A Hofman
P J Koudstaal
M M B Breteler
Erasmus MC · NL

Funding

Collaborative GWAS of Dementia, AD and related MRI and Cognitive EndophenotypesR01AG033193 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SESHADRI, SUDHA · 2009 to 2016
$4.4M
NIA NIH HHS 1 R01 AG 033 193-01
6 · The paper itself

Abstract

objectiveDiabetes mellitus has been associated with an increased risk of Alzheimer disease (AD), but how it exerts its effect remains controversial. Possible pathophysiologic mechanisms are glucose toxicity and a direct effect of insulin on amyloid metabolism. Most studies had short follow-up, and longer-term effects of diabetes on AD risk are unknown. We investigated whether fasting glucose and insulin levels and insulin resistance are associated with the risk of AD and whether this risk is constant over time.

methodsThe study was based on 3,139 participants of the Rotterdam Study, a population-based cohort study. All subjects were free from dementia, did not have a history of diabetes, and had fasting levels of glucose and insulin measured at baseline. Insulin resistance was estimated with the homeostasis model assessment. We investigated how fasting glucose, insulin, and insulin resistance are related to the risk of AD in 3 different strata according to time-to-event, using Cox proportional hazards models.

resultsDuring follow-up, 211 participants developed AD, 71 of them within 3 years of baseline. Levels of insulin and insulin resistance were associated with a higher risk of AD within 3 years of baseline. After 3 years, the risk was no longer increased. Glucose was not associated with a higher risk of AD. There was no interaction of APOE ε4 carriership and insulin metabolism on the risk of AD.

conclusionsOur findings suggest that insulin metabolism influences the clinical manifestation of AD only within 3 years.

Indexed as

Insulin ResistanceAgedAged, 80 and overAllelesAlzheimer DiseaseApolipoprotein E4Blood GlucoseCohort StudiesFemaleGenotypeHumansInsulinMaleMiddle AgedProportional Hazards ModelsRiskApolipoprotein E4Blood GlucoseInsulin

Identifiers

PMID21115952
PMCPMC3014236
OpenAlexW2084979315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.